pharma · Severe Acute Respiratory Syndrome-related Coronavirus
Yang I. Pachankis
Yang I. Pachankis is a pharma organization headquartered in CN. Primary therapeutic focus areas include Severe Acute Respiratory Syndrome-related Coronavirus. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s)
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Nifedipine 30 MG
Approved · small molecule · Severe Acute Respiratory Syndrome-related Coronavirus
Nifedipine 30 MG for Severe Acute Respiratory Syndrome-related Coronavirus is a Approved program (small_molecule) at Yang I. Pachankis with 1 ClinicalTrials.gov record(s).
Internal code SARSCoVVaxPoison
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Yang I. Pachankis
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Severe Acute Respiratory Syndrome-related Coronavirus
- Status
- completed
- Trials
- 1